TABLE 5.
Nonrespiratory outcomes
| Period 1 (n=675) | Period 2 (n=851) | Crude OR (95% CI) | Adjusted* OR (95% CI) | |
|---|---|---|---|---|
| NEC stage =2, n (%) | 22 (3) | 17 (2) | 0.6 (0.3–1.1) | 0.5 (0.3–1.1) |
| Sepsis (any), n (%) | 167 (25) | 250 (29) | 1.2 (1.0–1.5) | 1.2 (0.9–1.6) |
| IVH grade III or IV, n (%) | 11 (2) | 7 (1) | 0.5 (0.2–1.3) | 0.5 (0.2–1.4) |
| PVL, n (%) | 27 (4) | 17 (2) | 0.5 (0.2–0.9) | 0.5 (0.3–0.9) |
| ROP stage =3, n (%) | 18 (3) | 50 (6) | 2.1 (1.2–3.7) | 2.7 (1.4–5.2) |
| ROP treated, n (%) | 22 (3) | 42 (5) | 1.5 (0.9–2.6) | 1.7 (0.9–3.2) |
| PDA, n (%) | 201 (30) | 234 (27) | 0.8 (0.7–1.1) | 1.2 (0.9–1.5) |
*Adjusted for gestational age, birth weight, sex, presentation, delivery mode, small for gestational age, Apgar score at 1 min and 5 min, pregnancy-induced hypertension, surfactant, nasal continuous positive airway pressure days, mechanical ventilation days, supplemental oxygen days. IVH Intraventricular hemorrhage;
NEC Necrotizing enterocolitis;
PDA Patent ductus arteriosus; PVL Periventricular leukomalacia;
ROP Retinopathy of prematurity